Suppr超能文献

腺苷受体亚型

Adenosine receptor subtypes.

作者信息

Collis M G, Hourani S M

机构信息

Pfizer Central Research, Sandwich, UK.

出版信息

Trends Pharmacol Sci. 1993 Oct;14(10):360-6. doi: 10.1016/0165-6147(93)90094-z.

Abstract

The numerous and widespread effects of adenosine provide both an opportunity for the development of novel therapeutic agents acting via adenosine receptors and the challenge of achieving selectivity of action. The feasibility of achieving selectivity is enhanced if receptor subtypes can be identified. Biochemical, functional and receptor-cloning studies are beginning to provide convergent data supporting the existence of A1, A2A, A2B and A3 receptors. However, studies of the functional significance of these receptors in intact tissues both in vitro and in vivo have lagged behind the biochemical studies. In this article, Michael Collis and Susanna Hourani review the current status of adenosine receptor classification and propose that ligands with greater selectivity need to be evaluated in a wide range of functional preparations if the therapeutic potential of this area is to be realized.

摘要

腺苷具有众多广泛的作用,这既为开发通过腺苷受体起作用的新型治疗药物提供了机遇,也带来了实现作用选择性的挑战。如果能够识别受体亚型,实现选择性的可行性就会提高。生物化学、功能及受体克隆研究开始提供趋同的数据,支持A1、A2A、A2B和A3受体的存在。然而,这些受体在完整组织中体外及体内功能意义的研究落后于生物化学研究。在本文中,迈克尔·科利斯和苏珊娜·霍拉尼综述了腺苷受体分类的现状,并提出如果要实现该领域的治疗潜力,就需要在广泛的功能制剂中评估具有更高选择性的配体。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验